GlassScriptPhysician profile
Jim Cheng
NPI 1790122638
$3,834.90
in general payments reported to CMS, 2019-2025
30 companies · $94.41 in 2025
The $94.41 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $275 · 2022: $2,438 · 2023: $701 · 2024: $327 · 2025: $94.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $638.25 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $572.52 | 2022-2023 | Mounjaro, Jardiance, Lyumjev |
| Abbvie INC. | $424.11 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $321.78 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.10 | 2022-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $204.31 | 2021-2024 | Spravato |
| Cequr Corporation | $196.16 | 2022-2023 | Cequr Simplicity |
| Mannkind Corporation | $193.91 | 2022-2023 | Afrezza |
| Novartis Pharmaceuticals Corporation | $134.77 | 2022 | |
| Sanofi-Aventis U.S. LLC | $129.13 | 2022 | |
| Orthalign INC | $125.00 | 2021 | |
| Esperion Therapeutics, INC. | $124.99 | 2022 | |
| Novo Nordisk INC | $69.48 | 2022-2023 | Ozempic, Rybelsus |
| Amgen INC. | $63.60 | 2022-2023 | Repatha |
| Sunovion Pharmaceuticals INC. | $45.41 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $41.70 | 2022 | |
| Alkermes, INC. | $37.54 | 2021-2023 | Vivitrol |
| Corcept Therapeutics | $28.54 | 2023 | Korlym |
| Amryt Pharma Holdings LTD | $26.94 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.90 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.97 | 2022 | |
| Glaxosmithkline, LLC. | $21.41 | 2025 | Nucala |
| Calliditas Therapeutics US INC. | $19.28 | 2022 | |
| Ibsa Pharma INC. | $16.70 | 2022 | |
| Shield Therapeutics INC | $16.10 | 2023 | Accrufer |
| Antares Pharma, INC. | $16.00 | 2022 | |
| Acerus Pharmaceuticals Corporation | $15.50 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.91 | 2021 | |
| Tolmar, INC. | $14.20 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $13.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.